VEKLURY Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Veklury, and what generic alternatives are available?
Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are thirteen patents protecting this drug.
This drug has three hundred and one patent family members in forty-six countries.
The generic ingredient in VEKLURY is remdesivir. One supplier is listed for this compound. Additional details are available on the remdesivir profile page.
DrugPatentWatch® Generic Entry Outlook for Veklury
Veklury will be eligible for patent challenges on October 22, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 29, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VEKLURY
International Patents: | 301 |
US Patents: | 13 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 5 |
Patent Applications: | 39 |
What excipients (inactive ingredients) are in VEKLURY? | VEKLURY excipients list |
DailyMed Link: | VEKLURY at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VEKLURY
Generic Entry Date for VEKLURY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VEKLURY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mansoura University Hospital | Phase 4 |
PharmaMar | Phase 3 |
ASST Fatebenefratelli Sacco | Phase 3 |
Pharmacology for VEKLURY
Anatomical Therapeutic Chemical (ATC) Classes for VEKLURY
US Patents and Regulatory Information for VEKLURY
VEKLURY is protected by twenty-four US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VEKLURY is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VEKLURY
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Methods for treating arenaviridae and coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Methods for treating Arenaviridae and Coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Methods for treating Arenaviridae and Coronaviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALE THEREOF, IS NOT RECOMMENDED
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
Paramyxoviridae
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
1'-substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
1'substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methods for treating Filoviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methods for treating Filoviridae virus infections
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
1'-substituted carba-nucleoside analogs for antiviral treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting VEKLURY
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing
3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VEKLURY
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Ireland UC | Veklury | remdesivir | EMEA/H/C/005622 Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 |
Authorised | no | no | no | 2020-07-03 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VEKLURY
When does loss-of-exclusivity occur for VEKLURY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2467
Estimated Expiration: See Plans and Pricing
Patent: 2468
Estimated Expiration: See Plans and Pricing
Patent: 9850
Estimated Expiration: See Plans and Pricing
Australia
Patent: 15339222
Estimated Expiration: See Plans and Pricing
Patent: 15339223
Estimated Expiration: See Plans and Pricing
Patent: 18253483
Estimated Expiration: See Plans and Pricing
Patent: 19201232
Estimated Expiration: See Plans and Pricing
Patent: 20203892
Estimated Expiration: See Plans and Pricing
Patent: 21201474
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2015027413
Estimated Expiration: See Plans and Pricing
Patent: 2017007636
Estimated Expiration: See Plans and Pricing
Canada
Patent: 63832
Estimated Expiration: See Plans and Pricing
Patent: 63907
Estimated Expiration: See Plans and Pricing
Chile
Patent: 17001040
Estimated Expiration: See Plans and Pricing
Patent: 17002693
Estimated Expiration: See Plans and Pricing
China
Patent: 7073005
Estimated Expiration: See Plans and Pricing
Patent: 7074902
Estimated Expiration: See Plans and Pricing
Patent: 3549120
Estimated Expiration: See Plans and Pricing
Patent: 3620992
Estimated Expiration: See Plans and Pricing
Patent: 4191438
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 17003960
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 170165
Estimated Expiration: See Plans and Pricing
Patent: 170483
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0181130
Estimated Expiration: See Plans and Pricing
Patent: 0200518
Estimated Expiration: See Plans and Pricing
Cuba
Patent: 170056
Estimated Expiration: See Plans and Pricing
Patent: 170145
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 20893
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
Dominican Republic
Patent: 017000103
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 17025261
Estimated Expiration: See Plans and Pricing
Patent: 17072474
Estimated Expiration: See Plans and Pricing
El Salvador
Patent: 17005424
Estimated Expiration: See Plans and Pricing
Patent: 17005561
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 2239
Estimated Expiration: See Plans and Pricing
Patent: 9561
Estimated Expiration: See Plans and Pricing
Patent: 1790597
Estimated Expiration: See Plans and Pricing
Patent: 1790630
Estimated Expiration: See Plans and Pricing
Patent: 1990021
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 12175
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
Patent: 95844
Estimated Expiration: See Plans and Pricing
Patent: 36099
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 58795
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 39231
Estimated Expiration: See Plans and Pricing
Patent: 49192
Estimated Expiration: See Plans and Pricing
Israel
Patent: 1560
Estimated Expiration: See Plans and Pricing
Patent: 1707
Estimated Expiration: See Plans and Pricing
Japan
Patent: 20484
Estimated Expiration: See Plans and Pricing
Patent: 87547
Estimated Expiration: See Plans and Pricing
Patent: 71424
Estimated Expiration: See Plans and Pricing
Patent: 57294
Estimated Expiration: See Plans and Pricing
Patent: 17186358
Estimated Expiration: See Plans and Pricing
Patent: 17533903
Estimated Expiration: See Plans and Pricing
Patent: 17534614
Estimated Expiration: See Plans and Pricing
Patent: 18172424
Estimated Expiration: See Plans and Pricing
Patent: 19048901
Estimated Expiration: See Plans and Pricing
Patent: 20090536
Estimated Expiration: See Plans and Pricing
Patent: 20097635
Estimated Expiration: See Plans and Pricing
Patent: 22065066
Estimated Expiration: See Plans and Pricing
Patent: 22068297
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 17005250
Estimated Expiration: See Plans and Pricing
Patent: 17005252
Estimated Expiration: See Plans and Pricing
Moldova, Republic of
Patent: 170046
Estimated Expiration: See Plans and Pricing
Montenegro
Patent: 070
Estimated Expiration: See Plans and Pricing
Morocco
Patent: 867
Estimated Expiration: See Plans and Pricing
Patent: 872
Estimated Expiration: See Plans and Pricing
Patent: 201
Estimated Expiration: See Plans and Pricing
Patent: 506
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 0803
Estimated Expiration: See Plans and Pricing
Patent: 0809
Estimated Expiration: See Plans and Pricing
Peru
Patent: 171439
Estimated Expiration: See Plans and Pricing
Patent: 180202
Estimated Expiration: See Plans and Pricing
Philippines
Patent: 017500631
Estimated Expiration: See Plans and Pricing
Patent: 020551055
Estimated Expiration: See Plans and Pricing
Poland
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 12175
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 12175
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
Saudi Arabia
Patent: 7381419
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 425
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 202008772U
Estimated Expiration: See Plans and Pricing
Patent: 201702903T
Estimated Expiration: See Plans and Pricing
Patent: 201702904R
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 12174
Estimated Expiration: See Plans and Pricing
Patent: 12175
Estimated Expiration: See Plans and Pricing
Patent: 66295
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1800414
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1822348
Estimated Expiration: See Plans and Pricing
Patent: 2337664
Estimated Expiration: See Plans and Pricing
Patent: 2453808
Estimated Expiration: See Plans and Pricing
Patent: 170066665
Estimated Expiration: See Plans and Pricing
Patent: 170067898
Estimated Expiration: See Plans and Pricing
Patent: 170077167
Estimated Expiration: See Plans and Pricing
Patent: 210152015
Estimated Expiration: See Plans and Pricing
Spain
Patent: 74806
Estimated Expiration: See Plans and Pricing
Patent: 85034
Estimated Expiration: See Plans and Pricing
Patent: 04298
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 87432
Estimated Expiration: See Plans and Pricing
Patent: 98444
Estimated Expiration: See Plans and Pricing
Patent: 40546
Estimated Expiration: See Plans and Pricing
Patent: 67201
Estimated Expiration: See Plans and Pricing
Patent: 1629076
Estimated Expiration: See Plans and Pricing
Patent: 1630925
Estimated Expiration: See Plans and Pricing
Patent: 2039526
Estimated Expiration: See Plans and Pricing
Patent: 2115098
Estimated Expiration: See Plans and Pricing
Turkey
Patent: 1809518
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 1485
Estimated Expiration: See Plans and Pricing
Uruguay
Patent: 376
Estimated Expiration: See Plans and Pricing
Patent: 464
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VEKLURY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2020097635 | リボシドの調製のための方法 (METHODS FOR PREPARING RIBOSIDES) | See Plans and Pricing |
China | 114366745 | 治疗沙粒病毒科和冠状病毒科病毒感染的方法 (Methods of treating arenaviridae and coronaviridae virus infections) | See Plans and Pricing |
Brazil | 112017007636 | métodos para a preparação de ribosídeos | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VEKLURY
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2595980 | 20C1065 | France | See Plans and Pricing | PRODUCT NAME: REMDESIVIR OU UN SEL OU UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/20/1459 20200703 |
2595980 | C202030068 | Spain | See Plans and Pricing | PRODUCT NAME: REMDESIVIR O UNA SAL O UN ESTER FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1459; DATE OF AUTHORISATION: 20200703; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1459; DATE OF FIRST AUTHORISATION IN EEA: 20200703 |
2937350 | LUC00193 | Luxembourg | See Plans and Pricing | PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1459 20200703 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |